SAGE Therapeutics Initiates Exploratory Study of SAGE-547 in Essential Tremor
SAGE Therapeutics to Participate in the 2014 Leerink Partners Rare Disease Roundtable
SAGE Therapeutics Appoints Michael F. Cola to the Company's Board of Directors
SAGE Therapeutics is a neuroscience-focused company developing medicines to treat life-threatening, rare CNS disorders. SAGE’s lead program, SAGE-547, is in clinical development for super-refractory status epilepticus (SRSE) and is the first of many compounds the company is developing in its portfolio of potential seizure medicines. SAGE’s robust chemistry platform has generated multiple new compounds that target the GABAA and NMDA receptors, which have demonstrated preclinical activity. SAGE Therapeutics is a public company launched in 2010 by an experienced team of R&D leaders, CNS experts and investors.